Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1999 Jun;54(6):518–523. doi: 10.1136/thx.54.6.518

Oxidative stress during acute respiratory exacerbations in cystic fibrosis

L McGrath 1, P Mallon 1, L Dowey 1, B Silke 1, E McClean 1, M McDonnell 1, A Devine 1, S Copeland 1, S Elborn 1
PMCID: PMC1745483  PMID: 10335006

Abstract

BACKGROUND—Patients with cystic fibrosis experience chronic systemic oxidative stress. This is coupled with chronic inflammation of the lung involving bronchial polymorphonuclear neutrophil accumulation and activation. We hypothesised that, during periods of acute respiratory exacerbation, free radical activity and consequent damage would be most marked and that intensive treatment of the infection would result in improvement towards values found during stable periods.
METHODS—Plasma and red blood cells were collected from 12 healthy normal volunteers and from 12 patients with cystic fibrosis with an acute respiratory exacerbation (increased respiratory symptoms, reduction in forced expiratory volume in one second (FEV1) of more than 10%, and a decision to treat with intravenous antibiotics). Further samples were collected from patients following two weeks of treatment. Samples were analysed for inflammatory markers, markers of free radical damage, and aqueous and lipid phase scavengers.
RESULTS—During respiratory exacerbations FEV1 and forced vital capacity (FVC) were lower than in controls (mean differences -2.82 (95% CI -2.12 to -3.52) and -3.79 (-3.03 to -4.55) l, respectively) but improved following treatment (mean change 0.29 (95% CI 0.18to 0.40) and 0.33 (0.23 to 0.43) l, respectively). Inflammatory markers during exacerbations were significantly higher in patients than in controls with the following mean (95% CI) differences: C reactive protein (CRP), 46 (17 to 75) g/l; neutrophil elastase α1-antiprotease complexes (NEAPC), 4.4 (1.77 to 7.07) mg/l; white cell count (WCC), 5.3 (4.7 to 5.9) × 109/l. These markers decreased significantly following treatment with the following mean (95% CI) changes: CRP -26 (-10 to -42) g/l; NEAPC -3.1 (-1.3 to -4.9) mg/l; WCC -1.5 (-1.3 to -1.7) ×109/l. Malondialdehyde (MDA) as a marker of free radical activity was significantly higher in patients during exacerbations than in controls with a mean (95% CI) difference of 193 (107 to 279) which improved with treatment (mean change -56 (95% CI -28 to -84) nmol/mmol cholesterol). Red blood cell polyunsaturated fatty acids were significantly lower in patients than in controls with a mean difference of -4.4(95% CI -2.6 to -6.2) moles percent, but did not improve significantly after treatment. Protein carbonyls during exacerbations were not different from controls but did increase with treatment compared with levels during the exacerbation (mean change 0.39 (95% CI 0.11 to 0.67) µmol/g protein). Aqueous and lipid phase scavengers in patients during exacerbations were significantly lower than in controls with the following mean (95% CI) differences: ascorbate, -19.0 (-2.7 to -35.3) µmol/l; sulphydryls, -122 (-77 to -167) µmol/l; retinol, -237 (-47 to -427) nmol/mmol cholesterol; β-carotene, -52.8 (-11.8 to -93.8) nmol/mmol cholesterol; luteine, -50.4 (-10.4 to -90.4) nmol/mmol cholesterol; lycopene, -90.1 (-30.1 to -150.1) nmol/mmol cholesterol. Treatment resulted in improvement with the following mean (95% CI) changes: sulphydryls, 50 (32 to 68) µmol/l; retinol, 152 (47 to 257) nmol/mmol cholesterol; α- and β-carotene, 0.6 (0.0 to 1.2) and 7.6 (0.0 to 15.2) nmol/mmol cholesterol, respectively; α-tocopherol, 839 (283 to 1405) nmol/mmol cholesterol; and lycopene, 8.2 (0.0 to 16.2) nmol/mmol cholesterol.
CONCLUSIONS—Abnormalities of markers of inflammation, free radical activity, and radical scavengers were significantly more extreme during acute respiratory exacerbations and showed improvement with treatment. The need to provide protection from inflammation and free radical damage should therefore be dynamic and related to the inflammatory and oxidative processes.



Full Text

The Full Text of this article is available as a PDF (112.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ames B. N. Endogenous oxidative DNA damage, aging, and cancer. Free Radic Res Commun. 1989;7(3-6):121–128. doi: 10.3109/10715768909087933. [DOI] [PubMed] [Google Scholar]
  2. Brown R. K., Kelly F. J. Evidence for increased oxidative damage in patients with cystic fibrosis. Pediatr Res. 1994 Oct;36(4):487–493. doi: 10.1203/00006450-199410000-00013. [DOI] [PubMed] [Google Scholar]
  3. Brown R. K., Kelly F. J. Role of free radicals in the pathogenesis of cystic fibrosis. Thorax. 1994 Aug;49(8):738–742. doi: 10.1136/thx.49.8.738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brown R. K., Wyatt H., Price J. F., Kelly F. J. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Eur Respir J. 1996 Feb;9(2):334–339. doi: 10.1183/09031936.96.09020334. [DOI] [PubMed] [Google Scholar]
  5. Congden P. J., Bruce G., Rothburn M. M., Clarke P. C., Littlewood J. M., Kelleher J., Losowsky M. S. Vitamin status in treated patients with cystic fibrosis. Arch Dis Child. 1981 Sep;56(9):708–714. doi: 10.1136/adc.56.9.708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Feigal R. J., Shapiro B. L. Mitochondrial calcium uptake and oxygen consumption in cystic fibrosis. Nature. 1979 Mar 15;278(5701):276–277. doi: 10.1038/278276a0. [DOI] [PubMed] [Google Scholar]
  7. Holsclaw D. S., Jr Cystic fibrosis and pulmonary involvement from multiple perspectives. Semin Respir Infect. 1992 Sep;7(3):141–149. [PubMed] [Google Scholar]
  8. Homnick D. N., Cox J. H., DeLoof M. J., Ringer T. V. Carotenoid levels in normal children and in children with cystic fibrosis. J Pediatr. 1993 May;122(5 Pt 1):703–707. doi: 10.1016/s0022-3476(06)80008-9. [DOI] [PubMed] [Google Scholar]
  9. Langley S. C., Brown R. K., Kelly F. J. Reduced free-radical-trapping capacity and altered plasma antioxidant status in cystic fibrosis. Pediatr Res. 1993 Mar;33(3):247–250. doi: 10.1203/00006450-199303000-00008. [DOI] [PubMed] [Google Scholar]
  10. Levine R. L., Garland D., Oliver C. N., Amici A., Climent I., Lenz A. G., Ahn B. W., Shaltiel S., Stadtman E. R. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990;186:464–478. doi: 10.1016/0076-6879(90)86141-h. [DOI] [PubMed] [Google Scholar]
  11. McGrath L. T., Douglas A. F., McClean E., Brown J. H., Doherty C. C., Johnston G. D., Archbold G. P. Oxidative stress and erythrocyte membrane fluidity in patients undergoing regular dialysis. Clin Chim Acta. 1995 Mar 31;235(2):179–188. doi: 10.1016/0009-8981(95)06027-x. [DOI] [PubMed] [Google Scholar]
  12. McGrath L. T., Elliott R. J. Lipid analysis and fatty acid profiles of individual arterial atherosclerotic plaques. Anal Biochem. 1990 Jun;187(2):273–276. doi: 10.1016/0003-2697(90)90456-j. [DOI] [PubMed] [Google Scholar]
  13. McNurlan M. A., Tomkins A. M., Garlick P. J. The effect of starvation on the rate of protein synthesis in rat liver and small intestine. Biochem J. 1979 Feb 15;178(2):373–379. doi: 10.1042/bj1780373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Meyer K. C., Lewandoski J. R., Zimmerman J. J., Nunley D., Calhoun W. J., Dopico G. A. Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis. Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):580–585. doi: 10.1164/ajrccm/144.3_Pt_1.580. [DOI] [PubMed] [Google Scholar]
  15. Munro J. M., Cotran R. S. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest. 1988 Mar;58(3):249–261. [PubMed] [Google Scholar]
  16. Reilly P. M., Schiller H. J., Bulkley G. B. Pharmacologic approach to tissue injury mediated by free radicals and other reactive oxygen metabolites. Am J Surg. 1991 Apr;161(4):488–503. doi: 10.1016/0002-9610(91)91120-8. [DOI] [PubMed] [Google Scholar]
  17. Salh B., Webb K., Guyan P. M., Day J. P., Wickens D., Griffin J., Braganza J. M., Dormandy T. L. Aberrant free radical activity in cystic fibrosis. Clin Chim Acta. 1989 Apr 28;181(1):65–74. doi: 10.1016/0009-8981(89)90318-5. [DOI] [PubMed] [Google Scholar]
  18. Stocker R., Bowry V. W., Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1646–1650. doi: 10.1073/pnas.88.5.1646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Thurnham D. I., Smith E., Flora P. S. Concurrent liquid-chromatographic assay of retinol, alpha-tocopherol, beta-carotene, alpha-carotene, lycopene, and beta-cryptoxanthin in plasma, with tocopherol acetate as internal standard. Clin Chem. 1988 Feb;34(2):377–381. [PubMed] [Google Scholar]
  20. Tribble D. L., Aw T. Y., Jones D. P. The pathophysiological significance of lipid peroxidation in oxidative cell injury. Hepatology. 1987 Mar-Apr;7(2):377–386. doi: 10.1002/hep.1840070227. [DOI] [PubMed] [Google Scholar]
  21. Winklhofer-Roob B. M. Oxygen free radicals and antioxidants in cystic fibrosis: the concept of an oxidant-antioxidant imbalance. Acta Paediatr Suppl. 1994 Apr;83(395):49–57. doi: 10.1111/j.1651-2227.1994.tb13229.x. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES